Twist Bioscience Corporation (TWST) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -144.98M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 71.86M USD | Research and Development Expense |
| Selling, general and administration | 290.29M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-144.98M | (m) | (m) | $71.86M | $290.29M | (m) |
| 2026-03-31 | $-138.82M | (m) | (m) | $71.89M | $272.95M | (m) |
| 2025-12-31 | $-134.51M | (m) | (m) | $76.11M | $260.54M | (m) |
| 2025-09-30 | $-136.26M | (m) | (m) | $80.28M | $246.98M | (m) |
| 2025-06-30 | $-142.37M | (m) | (m) | $84.41M | $236.36M | (m) |
| 2025-03-31 | $-201.17M | (m) | (m) | $88.83M | $229.78M | (m) |
| 2024-12-31 | $-208.50M | (m) | (m) | $89.06M | $221.74M | (m) |
| 2024-09-30 | $-220.83M | (m) | (m) | $90.85M | $218.40M | (m) |
| 2024-06-30 | $-234.90M | (m) | (m) | $93.46M | $212.65M | (m) |
| 2024-03-31 | $-206.76M | (m) | (m) | $95.52M | $201.91M | (m) |
| 2023-12-31 | $-219.51M | (m) | (m) | $98.75M | $200.25M | (m) |
| 2023-09-30 | $-217.16M | (m) | (m) | $106.89M | $189.74M | (m) |
| 2023-06-30 | $-223.92M | (m) | (m) | $112.75M | $196.51M | (m) |
| 2023-03-31 | $-224.30M | (m) | (m) | $125.07M | $204.14M | (m) |
| 2022-12-31 | $-223.47M | (m) | (m) | $128.92M | $204.18M | (m) |
| 2022-09-30 | $-234.78M | (m) | (m) | $120.31M | $212.95M | (m) |
| 2022-06-30 | $-217.72M | (m) | (m) | $110.14M | $197.03M | (m) |
| 2022-03-31 | $-198.67M | (m) | (m) | $93.14M | $177.82M | (m) |
| 2021-12-31 | $-175.87M | (m) | (m) | $77.70M | $158.21M | (m) |
| 2021-09-30 | $-152.73M | (m) | (m) | $69.07M | $135.90M | (m) |
| 2021-06-30 | $-136.88M | (m) | (m) | $61.27M | $124.84M | (m) |
| 2021-03-31 | $-122.96M | (m) | (m) | $51.87M | $112.85M | (m) |
| 2020-12-31 | $-117.04M | (m) | (m) | $46.71M | $105.65M | (m) |
| 2020-09-30 | $-140.08M | (m) | (m) | $43.01M | $103.27M | (m) |
| 2020-06-30 | $-147.68M | (m) | (m) | $41.87M | $100.50M | (m) |
| 2020-03-31 | $-147.61M | (m) | (m) | $40.43M | $99.34M | (m) |
| 2019-12-31 | $-141.78M | (m) | (m) | $38.71M | $91.27M | (m) |
| 2019-09-30 | $-108.85M | (m) | (m) | $35.68M | $80.13M | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $-70.56M | (m) | (m) | $20.35M | $43.45M | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-58.48M | (m) | (m) | $19.17M | $26.06M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |